New York, NY – July 14, 2010 – New and improved multiple sclerosis (MS) drugs satisfying key unmet needs of oral administration and increased efficacy suggest a paradigm shift in MS therapy; ending the decade long dominance of interferon betas and Copaxone (glatiramer acetate, Teva) says independent analyst Datamonitor.
The Russian approval of Merck Serono’s Movectro (oral cladribine) is a landmark in the treatment for relapse-remitting MS (RRMS) patients, as it becomes the world’s first oral disease-modifying MS therapy to be granted marketing authorization beating Novartis’s Gilenia (fingolimod). Without Tysabri and Extavia launching, Movectro will become the first new MS therapy to enter the $200m Russian MS market in over a decade and this bodes well for European approval expected in the third quarter of 2010.
While winning the race for European approval, Datamonitor expects Movectro will lose out to Gilenia in the race to become the first oral MS therapy in the US. In June 2010, Gilenia received unanimous backing by FDA advisors to be approved for RRMS patients and this news comes as a blow to Merck Serono, days after it announced the resubmission of oral cladribine.
However, despite concerns over safety, Datamonitor believe these oral drugs are set to become the leading MS therapies by 2014. Currently Gilenia has the advantage of being recommended as a first-line therapy by the FDA advisory panel supported by robust clinical trial data. At this stage it is unclear whether Movectro will receive the same backing. Datamonitor forecast seven major market sales of $2.4 billion and $820m for Gilenia and Movectro, respectively at the end of the forecast period in 2019.
Trung Huynh, healthcare analyst at Datamonitor, comments: “Approval of Movectro in Russia is an important milestone for the MS market and will open the floodgates for other oral therapies. These new drugs will rapidly capture market share in this lucrative market and are set to be key growth drivers in the mid-term. The seven major MS market value is set to peak at $9.5 billion in 2014.”
** From the report Multiple Sclerosis | Next generation therapies signal start of new era
Trung Huynh is available for comment.
To arrange an interview or for further details regarding this release please contact Alicia Barrios in the Datamonitor press office on +1 570 687 9319, or email us_pr@datamonitor.com
For UK, please contact Joe Dixonon + 44 (0)161 238 4083. For Asia-Pacific, please contact Tanisha Kaul on +61 (0) 9601 6723. For India/Middle-East, please contact Aartee Sundheep on + 91 (40) 6672 9586
ABOUT DATAMONITOR
The Datamonitor Group (www.datamonitor.com) is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Sourcing, Technology and Telecoms industries. Combining our industry knowledge and experience, we assist more than 6,000 of the world’s leading companies in making better strategic and operational decisions.
